Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells (Q42437883)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 May 2013

Language	Label	Description	Also known as
English	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells	scientific article published on 29 May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

31 October 2017

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells (English)

1 reference

Europe PubMed Central

31 October 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Raffaele De Palma

17

1 reference

Europe PubMed Central

31 October 2017

12

object named as

Sabine Tejpar

0 references

Fortunato Ciardiello

18

object named as

Fortunato Ciardiello

1 reference

Europe PubMed Central

31 October 2017

Liberato Berrino

16

object named as

Liberato Berrino

1 reference

Europe PubMed Central

31 October 2017

author name string

Erika Martinelli

1

1 reference

Europe PubMed Central

31 October 2017

Teresa Troiani

2

1 reference

Europe PubMed Central

31 October 2017

Elena D'Aiuto

3

1 reference

Europe PubMed Central

31 October 2017

Floriana Morgillo

4

1 reference

Europe PubMed Central

31 October 2017

Donata Vitagliano

5

1 reference

Europe PubMed Central

31 October 2017

Anna Capasso

6

1 reference

Europe PubMed Central

31 October 2017

Sarah Costantino

7

1 reference

Europe PubMed Central

31 October 2017

Loreta Pia Ciuffreda

8

1 reference

Europe PubMed Central

31 October 2017

Francesco Merolla

9

1 reference

Europe PubMed Central

31 October 2017

Loredana Vecchione

10

1 reference

Europe PubMed Central

31 October 2017

Veerle De Vriendt

11

1 reference

Europe PubMed Central

31 October 2017

Anna Nappi

13

1 reference

Europe PubMed Central

31 October 2017

Vincenzo Sforza

14

1 reference

Europe PubMed Central

31 October 2017

Giulia Martini

15

1 reference

Europe PubMed Central

31 October 2017

language of work or name

0 references

publication date

29 May 2013

1 reference

Europe PubMed Central

31 October 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

31 October 2017

133

1 reference

Europe PubMed Central

31 October 2017

9

1 reference

Europe PubMed Central

31 October 2017

2089-2101

1 reference

Europe PubMed Central

31 October 2017

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Targeting the PI3K signaling pathway in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Therapeutic potential of phosphoinositide 3-kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

PI3K pathway alterations in cancer: variations on a theme

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

RAS Interaction with PI3K: More Than Just Another Effector Pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Targeting RAS signalling pathways in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

The phosphoinositide 3-kinase pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Targeting PI3K/mTOR signaling in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

WWP2 is an E3 ubiquitin ligase for PTEN.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Identifiers

10.1002/IJC.28236

1 reference

Europe PubMed Central

31 October 2017

1 reference

Europe PubMed Central

31 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42437883&oldid=1944934255"